Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 6/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.43 |
| ▸ | ERN1 | O75460 | 3/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974107 | 0.93 | TEK (0.52) | TEKCDK4GSK3BPDE10AAURKB | |
| SCHEMBL974134 | 0.86 | TEK (0.52) | TEKCDK4GSK3BPDE10AAURKB | |
| SCHEMBL974459 | 0.85 | TEK (0.54) | TEKPDE10AAURKBKDRAURKA | |
| SCHEMBL971767 | 0.81 | TEK (0.58) | TEKCDK4GSK3BPDE10AAURKB | |
| SCHEMBL974780 | 0.81 | TEK (0.79) | TEKPDE10AAURKBKDRAURKA | |
| SCHEMBL1265961 | 0.78 | KDR (0.48) | TEKCDK4GSK3BAURKBKDR | |
| SCHEMBL12895674 | 0.78 | RAF1 (0.47) | TEKCDK4GSK3BKDR | |
| SCHEMBL1264404 | 0.77 | EPHX2 (0.54) | TEKCDK4GSK3BAURKBKDR | |
| SCHEMBL974057 | 0.77 | TEK (0.58) | TEKGSK3BPDE10AAURKBKDR | |
| SCHEMBL976103 | 0.76 | TEK (0.57) | TEKGSK3BPDE10AAURKBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868177-B2 | Multi-cyclic compounds and method of use | AMGEN INC. (US) | 2011-01-11 | — | — | US | claimed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | claimed |
| EP-1994030-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | Amgen Inc. (US) | 2008-11-26 | — | — | EP | claimed |
| US-20070213325-A1 | Multi-cyclic compound and method of use | AMGEN INC. (US) | 2007-09-13 | — | — | US | claimed |
| WO-2007100646-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2007-09-07 | — | — | WO | claimed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213325-A1 | Multi-cyclic compound and method of use | TIE1, CDK1, CCNB1 | TEK 22/4885CDK4 9/4885GSK3B 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.